TScan Therapeutics, Inc. (NASDAQ:TCRX)
Insiders here have filed 2 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
Loses money on what it sells.
- Revenue
- $7.1M
- Net income
- -$117.7M
- Net margin
- -1655.4%
Heavily indebted for what it earns.
- Total debt
- $90.9M
- Cash
- $100.2M
- Debt / equity
- 1.32
Comfortably covers what is due within a year.
- Current assets
- $104.4M
- Current liabilities
- $31.0M
- Current ratio
- 3.37
Consumes cash and must keep raising it.
- Operating cash flow
- -$116.3M
- Free cash flow
- -$118.4M
- FCF margin
- -1665.6%
Burning cash with under a year of runway — expect a raise.
- Shares outstanding
- 129.9M
- Share growth (1y)
- 0.2%
- Cash runway
- 10 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
TCRX Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 1.05 M | 982.00 K | 2.57 M | 2.51 M | 3.08 M | 2.17 M |
| Revenue Growth (YoY) | -65.83 % | -54.77 % | 286.02 % | 139.37 % | 473.88 % | 283.57 % |
| Cost of Revenue | 0.00 | 693.00 K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.05 M | 289.00 K | 2.57 M | 2.51 M | 3.08 M | 2.17 M |
| SG&A Expense | 8.14 M | 8.22 M | 5.73 M | 7.70 M | 8.92 M | 8.46 M |
| R&D Expense | 23.40 M | 21.90 M | 20.04 M | 31.69 M | 32.63 M | 29.79 M |
| Operating Expenses | 31.54 M | 29.43 M | 26.43 M | 39.56 M | 41.73 M | 38.42 M |
| Operating Income | -30.49 M | -29.14 M | -23.86 M | -37.05 M | -38.65 M | -36.25 M |
| Pretax Income | -30.36 M | -28.67 M | -22.98 M | -35.71 M | -36.95 M | -34.13 M |
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -30.36 M | -28.67 M | -22.98 M | -35.71 M | -36.95 M | -34.13 M |
| EPS (Basic) | -0.23 | -0.22 | -0.18 | -0.28 | -0.28 | -0.26 |
| EPS (Diluted) | -0.23 | -0.22 | -0.18 | -0.28 | -0.28 | -0.26 |
| Shares Outstanding | 129.95 M | 129.91 M | 129.86 M | 129.84 M | 129.73 M | 129.68 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.